Skip to main content

Table 2 Treatment characteristics

From: Comparing simultaneous integrated boost vs sequential boost in anal cancer patients: results of a retrospective observational study

Variable

N (%)

Boost approach

 SeqB

103 (54.3)

 SIB

87 (45.7)

SIB dose and fractionation

 PTV dose-tumor (Gy)

  54 Gy/30 fractions

57 (65.5)

  50.4 Gy/28 fractions

30 (34.5)

 PTV dose-positive nodes (Gy) (26 pts)

  50.4 Gy/30 fractions

26 (100.0)

 PTV dose-negative nodes (Gy)

  45 Gy/30 fractions

53 (60.9)

  42 Gy/28 fractions

34 (39.1)

SeqB dose and fractionation

 PTV dose-first sequence

  36 Gy/20 fractions

103 (100)

 PTV dose-sequential boost

  23,4 Gy/13 fractions

103 (100)

Chemotherapy regimens

  5-FU + MMC × 2 cycles

159 (83.7)

  5-FU + MMC × 1 cycle

2 (1.0)

  Capecitabine + MMC × 2 cycles

26 (13.7)

  Capecitabine + MMC × 1 cycle

3 (1.6)

  1. Legend, SeqB sequential boost, SIB simultaneous integrated boost, PTV planning target volume, Gy Gray, pts patients, 5-FU 5-fluorouracil, MMC mitomycin C